PROCEPT BIOROBOTICS CORP

Company Overview

Procept BioRobotics is a California‑based surgical robotics company that sells the AquaBeam and next‑generation HYDROS systems to perform image‑guided, automated, heat‑free Aquablation therapy for benign prostatic hyperplasia (BPH). The company operates a capital‑plus‑consumable commercial model (systems + single‑use handpieces), reported $224.5M revenue and a $91.4M net loss in 2024, and had an install base of 647 systems globally (505 U.S. at 12/31/2024; 762 systems as of mid‑2025). Growth and margins are driven by system placements and recurring handpiece utilization, while adoption depends critically on reimbursement/coverage (Medicare/local decisions, private payors) and regulatory/clinical progress. Key operational risks include single‑source suppliers, regulatory clearance/maintenance, clinical adoption pace and manufacturing scale.

Executive Compensation Practices

Compensation for executives at Procept is likely structured to align with commercialization and utilization metrics: system placements, handpiece (consumable) sales, revenue growth and improving gross margins are the clearest performance levers described in filings. Given the company’s scale‑up profile, pay packages commonly combine base salary, annual cash incentives tied to near‑term growth/operating targets, and significant equity awards (stock options/RSUs/PSUs) to reward long‑term adoption, margin expansion and strategic milestones (e.g., regulatory approvals, CPT coding, clinical trial endpoints). The filings note material stock‑based compensation and ASC 606/remeasurement items that can create volatility in reported earnings, so equity‑heavy incentives are likely used to conserve cash while retaining executives. Loan covenants, near‑term liquidity needs and ongoing R&D/commercial investments also create pressure to design compensation that balances retention with cash conservation and milestone‑based payouts.

Insider Trading Considerations

Insider trading activity at Procept will often track commercialization and reimbursement inflection points: system placement updates, quarter‑to‑quarter handpiece utilization, Medicare/local coverage decisions, the new Category I CPT code (effective 1/1/2026), and clinical trial/regulatory news (e.g., WATER IV PCa). Expect a mix of equity‑related transactions tied to routine option exercises/RSU vesting (to cover tax liabilities) and occasional strategic sales around financings (the Oct 2024 equity raise) or loan covenant amendments (Aug 2025), so distinguish routine liquidity‑driven sales from informational trades. Typical controls—Section 16 reporting, blackout windows around earnings and clinical releases, and 10b5‑1 plans—are likely in place; unusually timed or clustered insider sales around payer or clinical announcements warrant closer scrutiny given the company’s reliance on adoption and reimbursement outcomes.